Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
As F-star starts its transition into a clinical stage company underpinned by two proprietary bispecific compounds due to enter clinic late 2019, Eliot Forster joins the company as CEO with plans to expand the company’s regulatory and clinical operations capabilities and raise new funds.
Executives On The Move: Changes at the Top Ahead for Pfizer, New Division President at Bayer, and Advisors for VBI Vaccines.
A change will kick off 2019 for Pfizer when it promotes its COO to CEO. Bayer has a new president, pharmaceuticals, Americas, while VBI Vaccines announces the formation of three scientific and clinical advisory boards.
Cipla’s global head (operations) Raju Subramanyam is leaving the firm to pursue his own ambitions. The exit has resulted in an interesting portfolio rejig at the Mumbai-based firm, known for its generally clear manufacturing compliance record.
Executives On The Move: In the Commercial Arena, Shifting Positions at Mitsubishi, Tocagen, Shire and Vertex
This week we note shifts in the commercial arena. A new VP of sales and marketing at Mitsubishi Tanabe Pharma America and head of commercial at Tocagen. At the same time, a marketing lead departs Shire and the head of commercial, North America, exits Vertex Pharma.
Oxstem, ProMIS Neurosciences, resTORbio and Ultragenyx Pharmaceuticals are among firms recently announcing senior executive hires from the management ranks of big pharma. Meanwhile, Boehringer Ingelheim, Kane Biotech and Relypsa have all reported fresh resignations.
Executives On The Move: New CEOs Vaxil Bio and Akero Therapeutics, with Some Big Pharma Execs Joining Smaller Companies
This week’s appointments include a new chief business officer at Sutro Biopharma and a new chief medical officer at Crescendo Biologics. In addition, management from AstraZeneca and Gilead Biosciences take on the CEO role at smaller firms.
Executive All-Change: Bayer's Weinand To Join Sanofi, While Sanofi's Oelrich To Take His Place At Bayer
A head-spinning change of executives in Europe's leading pharmaceutical companies will see a new head of pharmaceuticals at Bayer and the former incumbent fetching up at Sanofi in the US.
We report this week company promotions: at Teva Pharmaceutical Industries a new president of API and Biologics Operations, and at Aileron Therapeutics a new President and CEO. Also, we announce in new hires a chief commercial officer at Halozyme Therapeutics and a CEO at Rheos Medicines.
Executives On The Move: Management Changes at Bristol-Myers Squibb Company, Merck KGaA And Eli Lilly
This week’s appointments include a new chief commercial officer at Bristol-Myers Squibb, a global head of innovation medicine at Merck KGaA, and president at Lilly Oncology.
Executives On The Move: New Hires at Achillion And Bayer, And Promotions At Allegro Ophthalmics And Merz Pharma
This week’s new appointments include C-level promotions at Allegro Ophthalmics, Merz Pharma and Athenex. In addition, new directors joined the boards of Dicerna Pharmaceuticals and Spring Bank Pharmaceuticals.
Scrip’s new-look appointments feature brings you details of new hires and promotions within the pharma and biotech world from the past week. It includes a new CEO at i2 Pharmaceuticals and other senior appointments at Achillion Pharmaceuticals, Hikma Pharmaceuticals USA and Portola Pharmaceuticals. Click on the table heading tabs to see details of the industry’s latest company moves and promotions.
Appointments: Senior Hires At Allergan, Novartis, Array Biopharma, Zelluna Immunotherapy, Grail, Alzheon And Sigilon Therapeutics
Pfizer Oncology has lost its CMO to Allergan, while Novartis beefs up its ethical leadership, Array Biopharma appoints a new chair and Sigilon raids Bioverativ for its new CEO.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.